Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Ribociclib Placebo|DRUG: Ribociclib|DRUG: NSAI: Letrozole or Anastrazole|DRUG: Letrozole|DRUG: Goserelin
Sponsor: Novartis Pharmaceuticals